ICC NF155:
- Blocking solution: Goat serum 5 % diluted in PBS.
- Patient’s sera diluted 1/100
- Primary antibody (anti-NF AF3235) diluted 1/1000.
- Secondary antibodies: GAC 488 + GAH 594 IgG (1/1000)
- Vectashield mounting medium.
Samples and result:
| Sample | Result | Sample | Result |
| 19-044 | – | 19-055 | – |
| 19-051 | – | 19-057 | – |
| 19-052 | – | Neg.control | – |
| 19-053 | – | Pos. control 15-226 | + |
ICC CNTN1:
- Blocking solution: Rabbit serum diluted 1/40 in PBS.
- Patient’s sera diluted 1/100
- Primary antibody (anti-CNTN1 AF904) diluted 1/1000.
- Secondary antibodies: RAG 488 + RAH 594 IgG (1/1000)
- Vectashield mounting medium.
Samples and result:
| Sample | Result | Sample | Result |
| AVP (154-18) | + | 19-057 | – |
| 19-051 | – | Neg. control | – |
| 19-052 | – | Pos. control 15-198 | + |
| 19-053 | – |
ICC CNTN1-CASPR1:
- Blocking solution: Goat serum 5 % diluted in PBS.
- Patient’s sera diluted 1/100
- Primary antibody (anti-CASPR1) diluted 1/250.
- Secondary antibodies: GAR 488 + GAH 594 IgG (1/1000)
- Vectashield mounting medium.
Samples and result:
| Sample | Result | Sample | Result |
| 19-037 | – | 19-052 | – |
| 19-038 | – | 19-053 | – |
| 19-044 | – | 19-056 | – |
| 19-045 | – | 19-057 | – |
| 19-049 | – | Neg.control | – |
| 19-050 | – | Pos.control 17-595 | + |
| 19-051 | – |
ICC NF140 and NF186:
- Blocking solution: Goat serum 5 % diluted in PBS.
- Patient’s sera diluted 1/100
- Primary antibody (anti-NF AF3235) diluted 1/1000.
- Secondary antibodies: GAC 488 + GAH 594 IgG (1/1000)
- Vectashield mounting medium.
Samples and result:
| Sample | NF140 | NF186 | Sample | NF140 | NF186 |
| 19-044 | – | – | 19-054 | + | – |
| 19-047 | + | – | 19-055 | – | – |
| 19-048 | – | – | 19-057 | – | – |
| 19-051 | – | – | Neg. control | – | – |
| 19-052 | – | – | Pos. control 16-069 | + | + |
| 19-053 | – | – |
